MIMEDX GROUP INC (MDXG) Fundamental Analysis & Valuation

NASDAQ:MDXG • US6024961012

Current stock price

3.92 USD
0 (0%)
At close:
3.92 USD
0 (0%)
After Hours:

This MDXG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. MDXG Profitability Analysis

1.1 Basic Checks

  • In the past year MDXG was profitable.
  • MDXG had a positive operating cash flow in the past year.
  • In multiple years MDXG reported negative net income over the last 5 years.
  • In multiple years MDXG reported negative operating cash flow during the last 5 years.
MDXG Yearly Net Income VS EBIT VS OCF VS FCFMDXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 14.18%, MDXG belongs to the top of the industry, outperforming 94.57% of the companies in the same industry.
  • MDXG's Return On Equity of 18.94% is amongst the best of the industry. MDXG outperforms 95.16% of its industry peers.
  • MDXG's Return On Invested Capital of 16.82% is amongst the best of the industry. MDXG outperforms 96.32% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for MDXG is significantly below the industry average of 27.73%.
  • The 3 year average ROIC (16.63%) for MDXG is below the current ROIC(16.82%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 14.18%
ROE 18.94%
ROIC 16.82%
ROA(3y)16.58%
ROA(5y)3.91%
ROE(3y)24.51%
ROE(5y)1.29%
ROIC(3y)16.63%
ROIC(5y)N/A
MDXG Yearly ROA, ROE, ROICMDXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

1.3 Margins

  • MDXG has a Profit Margin of 11.60%. This is amongst the best in the industry. MDXG outperforms 91.47% of its industry peers.
  • The Operating Margin of MDXG (15.26%) is better than 92.25% of its industry peers.
  • In the last couple of years the Operating Margin of MDXG has grown nicely.
  • The Gross Margin of MDXG (82.56%) is better than 85.66% of its industry peers.
  • In the last couple of years the Gross Margin of MDXG has remained more or less at the same level.
Industry RankSector Rank
OM 15.26%
PM (TTM) 11.6%
GM 82.56%
OM growth 3YN/A
OM growth 5Y20.19%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5Y-0.38%
MDXG Yearly Profit, Operating, Gross MarginsMDXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. MDXG Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MDXG is creating value.
  • The number of shares outstanding for MDXG has been increased compared to 1 year ago.
  • Compared to 5 years ago, MDXG has more shares outstanding
  • MDXG has a better debt/assets ratio than last year.
MDXG Yearly Shares OutstandingMDXG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
MDXG Yearly Total Debt VS Total AssetsMDXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • MDXG has an Altman-Z score of 6.47. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
  • MDXG has a Altman-Z score of 6.47. This is in the better half of the industry: MDXG outperforms 76.16% of its industry peers.
  • The Debt to FCF ratio of MDXG is 0.25, which is an excellent value as it means it would take MDXG, only 0.25 years of fcf income to pay off all of its debts.
  • MDXG has a better Debt to FCF ratio (0.25) than 95.54% of its industry peers.
  • MDXG has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of MDXG (0.06) is worse than 60.27% of its industry peers.
  • Although MDXG's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.25
Altman-Z 6.47
ROIC/WACC1.84
WACC9.13%
MDXG Yearly LT Debt VS Equity VS FCFMDXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • A Current Ratio of 4.32 indicates that MDXG has no problem at all paying its short term obligations.
  • MDXG has a Current ratio of 4.32. This is comparable to the rest of the industry: MDXG outperforms 50.19% of its industry peers.
  • MDXG has a Quick Ratio of 3.92. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of MDXG (3.92) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.32
Quick Ratio 3.92
MDXG Yearly Current Assets VS Current LiabilitesMDXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MDXG Growth Analysis

3.1 Past

  • MDXG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.38%, which is quite impressive.
  • The Revenue has grown by 19.99% in the past year. This is quite good.
  • The Revenue has been growing by 11.02% on average over the past years. This is quite good.
EPS 1Y (TTM)41.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)19.99%
Revenue growth 3Y16.06%
Revenue growth 5Y11.02%
Sales Q2Q%27.11%

3.2 Future

  • Based on estimates for the next years, MDXG will show a small growth in Earnings Per Share. The EPS will grow by 1.82% on average per year.
  • The Revenue is expected to grow by 4.92% on average over the next years.
EPS Next Y-72.63%
EPS Next 2Y-24.36%
EPS Next 3Y-7.32%
EPS Next 5Y1.82%
Revenue Next Year-15.29%
Revenue Next 2Y-2.15%
Revenue Next 3Y2.1%
Revenue Next 5Y4.92%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MDXG Yearly Revenue VS EstimatesMDXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
MDXG Yearly EPS VS EstimatesMDXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 0.4

More info and screens

Find the best growth stocksShow best growing peers

6

4. MDXG Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 9.56, the valuation of MDXG can be described as reasonable.
  • Based on the Price/Earnings ratio, MDXG is valued cheaply inside the industry as 96.71% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 27.34, MDXG is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 34.94, the valuation of MDXG can be described as expensive.
  • MDXG's Price/Forward Earnings ratio is rather cheap when compared to the industry. MDXG is cheaper than 91.86% of the companies in the same industry.
  • MDXG's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 38.18.
Industry RankSector Rank
PE 9.56
Fwd PE 34.94
MDXG Price Earnings VS Forward Price EarningsMDXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 97.87% of the companies listed in the same industry.
  • 98.45% of the companies in the same industry are more expensive than MDXG, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 7.98
EV/EBITDA 5.51
MDXG Per share dataMDXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

  • MDXG has a very decent profitability rating, which may justify a higher PE ratio.
  • A cheap valuation may be justified as MDXG's earnings are expected to decrease with -7.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.36%
EPS Next 3Y-7.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MDXG Dividend Analysis

5.1 Amount

  • No dividends for MDXG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MDXG Fundamentals: All Metrics, Ratios and Statistics

MIMEDX GROUP INC

NASDAQ:MDXG (4/14/2026, 8:00:01 PM)

After market: 3.92 0 (0%)

3.92

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners73.24%
Inst Owner Change0.59%
Ins Owners2.34%
Ins Owner Change1.43%
Market Cap582.39M
Revenue(TTM)418.63M
Net Income(TTM)48.58M
Analysts81.67
Price Target9.86 (151.53%)
Short Float %5.29%
Short Ratio7.29
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)63.4%
Min EPS beat(2)16.71%
Max EPS beat(2)110.08%
EPS beat(4)4
Avg EPS beat(4)53.83%
Min EPS beat(4)6.95%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)37.48%
EPS beat(12)11
Avg EPS beat(12)67.57%
EPS beat(16)12
Avg EPS beat(16)46.59%
Revenue beat(2)2
Avg Revenue beat(2)13.43%
Min Revenue beat(2)8.43%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)8.47%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)4.52%
Revenue beat(12)10
Avg Revenue beat(12)4.59%
Revenue beat(16)12
Avg Revenue beat(16)3.74%
PT rev (1m)0%
PT rev (3m)-20.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-180%
EPS NY rev (1m)-2.94%
EPS NY rev (3m)-55.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-27.28%
Revenue NY rev (1m)-0.68%
Revenue NY rev (3m)-17.07%
Valuation
Industry RankSector Rank
PE 9.56
Fwd PE 34.94
P/S 1.39
P/FCF 7.98
P/OCF 7.87
P/B 2.27
P/tB 2.61
EV/EBITDA 5.51
EPS(TTM)0.41
EY10.46%
EPS(NY)0.11
Fwd EY2.86%
FCF(TTM)0.49
FCFY12.53%
OCF(TTM)0.5
OCFY12.71%
SpS2.82
BVpS1.73
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.99
Profitability
Industry RankSector Rank
ROA 14.18%
ROE 18.94%
ROCE 22.95%
ROIC 16.82%
ROICexc 41.72%
ROICexgc 59.54%
OM 15.26%
PM (TTM) 11.6%
GM 82.56%
FCFM 17.43%
ROA(3y)16.58%
ROA(5y)3.91%
ROE(3y)24.51%
ROE(5y)1.29%
ROIC(3y)16.63%
ROIC(5y)N/A
ROICexc(3y)34.07%
ROICexc(5y)N/A
ROICexgc(3y)46.74%
ROICexgc(5y)N/A
ROCE(3y)22.68%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y2.46%
ROICexc growth 3YN/A
ROICexc growth 5Y12.11%
OM growth 3YN/A
OM growth 5Y20.19%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5Y-0.38%
F-Score5
Asset Turnover1.22
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.25
Debt/EBITDA 0.21
Cap/Depr 6.94%
Cap/Sales 0.25%
Interest Coverage 51.27
Cash Conversion 93.95%
Profit Quality 150.21%
Current Ratio 4.32
Quick Ratio 3.92
Altman-Z 6.47
F-Score5
WACC9.13%
ROIC/WACC1.84
Cap/Depr(3y)32.56%
Cap/Depr(5y)46.17%
Cap/Sales(3y)0.47%
Cap/Sales(5y)0.75%
Profit Quality(3y)118.38%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-72.63%
EPS Next 2Y-24.36%
EPS Next 3Y-7.32%
EPS Next 5Y1.82%
Revenue 1Y (TTM)19.99%
Revenue growth 3Y16.06%
Revenue growth 5Y11.02%
Sales Q2Q%27.11%
Revenue Next Year-15.29%
Revenue Next 2Y-2.15%
Revenue Next 3Y2.1%
Revenue Next 5Y4.92%
EBIT growth 1Y26.23%
EBIT growth 3YN/A
EBIT growth 5Y33.44%
EBIT Next Year-18.28%
EBIT Next 3Y13.89%
EBIT Next 5Y12.12%
FCF growth 1Y13.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.79%
OCF growth 3YN/A
OCF growth 5YN/A

MIMEDX GROUP INC / MDXG Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?

ChartMill assigns a fundamental rating of 6 / 10 to MDXG.


Can you provide the valuation status for MIMEDX GROUP INC?

ChartMill assigns a valuation rating of 6 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Fairly Valued.


How profitable is MIMEDX GROUP INC (MDXG) stock?

MIMEDX GROUP INC (MDXG) has a profitability rating of 7 / 10.


What is the valuation of MIMEDX GROUP INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for MIMEDX GROUP INC (MDXG) is 9.56 and the Price/Book (PB) ratio is 2.27.


Can you provide the expected EPS growth for MDXG stock?

The Earnings per Share (EPS) of MIMEDX GROUP INC (MDXG) is expected to decline by -72.63% in the next year.